We are live on ! Find out more
DMPV

Delphi Management Partners VIII Portfolio holdings

AUM $138M
1-Year Est. Return 56.74%
This Fund
S&P 500
This Quarter Est. Return
+2.1%
1 Year Est. Return
+56.74%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$152M
AUM Growth
Cap. Flow
+$154M
Cap. Flow %
100.95%
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 92.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TNDM icon
1
Tandem Diabetes Care
TNDM
$1.17B
$95.7M 62.89%
+1,000,000
New +$103M
KPTI icon
2
Karyopharm Therapeutics
KPTI
$216M
$35M 23.03%
+150,867
New +$35M
CALA
3
DELISTED
Calithera Biosciences, Inc
CALA
$11.9M 7.83%
+121,335
New +$10.6M
SENS icon
4
Senseonics Holdings Inc
SENS
$267M
$8.59M 5.64%
+492,315
New +$4.29M
MREO
5
Mereo BioPharma
MREO
$49.5M
$919K 0.6%
+256,734
New +$643K

Similar funds

Delphi Management Partners VIII's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Delphi Management Partners VIII, which disclosed 5 positions worth $152M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Tandem Diabetes Care: 1,000,000 shares worth $95.7M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets.

  • Delphi Management Partners VIII's largest Q4 2020 buy was Tandem Diabetes Care: 1,000,000 shares worth $95.7M.
  • Delphi Management Partners VIII's ten largest holdings make up 100% of its $152M portfolio in Q4 2020.
  • Delphi Management Partners VIII disclosed 5 positions in Q4 2020, its first 13F filing on record.

Based on Delphi Management Partners VIII's 13F filing for Q4 2020, filed 8 Feb 2021.